Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.85 EUR

+3.94 %

2,190 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

+3.94 %
+3.42 %
-21.78 %
-25.86 %
-30.60 %
-46.80 %
-55.09 %
-
-63.52 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
62.19M EUR
Turnover
52K EUR
P/E (adj.) (26e)
-7.45
EV/EBIT (adj.) (26e)
-7.7
P/B (26e)
4.6
EV/S (26e)
13.76
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
2026-03-08
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2026-03-09

Latest extensive report

Released: 2025-04-24

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/5
2026

Extraordinary general meeting '26

28/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Keep these coming, more and more, although they are unfortunately slow to monetize. The wait is long, especially since all parties must proceed slowly through pilots for each cancer type separately before this becomes mainstream. *> Aiforia selected as AI partner for PROSTIA project...
4/16/2026, 9:10 AM
by Opa
34
Here are Siltanen’s comments regarding the recent news above. Aiforia announced on Thursday that it has been selected as the AI partner for the French PROSTIA project. With the agreement, the company’s prostate cancer diagnostic solution will be implemented in five new Assistance...
4/17/2026, 4:52 AM
by Sijoittaja-alokas
19
Well, what do you know, it hit the mark! The hint was this funding, where a project by a Dana-Farber researcher matched a bit too precisely what Aiforia’s earlier press release opened up about. MLSC – 22 Dec 25 Healey-Driscoll Administration Announces More Than $20 Million in Life...
4/14/2026, 4:27 PM
by Puutaheinää
19
aiforia.com Aiforia Announces Collaboration on Bladder Cancer Research with Renowned... Aiforia and Dana-Farber Cancer Institute partner to advance bladder cancer treatment using Aiforia® Create-built AI solution.
4/14/2026, 4:18 PM
by Salvelinus
16
There were also inklings of this on December 25th In itself, it’s quite a niche area: predicting treatment outcomes for metastatic bladder cancer. They combine Aiforia’s tools and expertise in histology with spatial transcriptomics, which is a map of which genes are expressed in ...
4/15/2026, 5:57 AM
by Vino Pino
13
The minutes of the General Meeting can be found on Aiforia’s website (investors/AGM2026) It was a close call; 65% voted in favor, while 2/3 (66.67%) was required. The EGM indeed has the same proposal, so if the opposing shareholders had an alternative financing plan, the board hasn...
4/15/2026, 9:55 AM
by Puutaheinää
9
An explanation has now been provided for the blocking of the share issue at the Annual General Meeting: “The shareholder who requested the Extraordinary General Meeting has stated that the voting result was caused by technical and administrative difficulties encountered by several...
4/15/2026, 6:31 AM
by Vino Pino
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.